1-7 of 7
Junji Matsui
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C008: Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cancer

Yan Zhang, Bob Zimmermann, Shuyu Li, Toshimitsu Uenaka, Keiji Furuuchi, Kan Yonemori, Toshio Shimizu, Shin Nishio, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Yohei Otake, Takuma Miura, Junji Matsui, Meijuan Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C008.
https://doi.org/10.1158/1535-7163.TARG-23-C008
Published: 01 December 2023
View articletitled, Abstract C008: Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cancer
Journal Articles

ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs

Shuntaro Tsukamoto, Naoko Hata Sugi, Kyoko Nishibata, Youya Nakazawa, Daisuke Ito, Sayo Fukushima, Takayuki Nakagawa, Kenji Ichikawa, Yu Kato, Dai Kakiuchi, Aya Goto, Machiko Itoh-Yagi, Tomoki Aota, Satoshi Inoue, Yoshinobu Yamane, Norio Murai, Hiroshi Azuma, Satoshi Nagao, Ken Sasai, Tsuyoshi Akagi, Toshio Imai, Junji Matsui, Tomohiro Matsushima
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (1): 12–24.
https://doi.org/10.1158/1535-7163.MCT-21-0879
Published: 03 January 2023
View articletitled, ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
Open the PDF for ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs in another window
Includes: Supplementary data
Journal Articles

Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice

Rong Wang, Tadaaki Yamada, Sachiko Arai, Koji Fukuda, Hirokazu Taniguchi, Azusa Tanimoto, Akihiro Nishiyama, Shinji Takeuchi, Kaname Yamashita, Koshiro Ohtsubo, Junji Matsui, Naoyoshi Onoda, Eishu Hirata, Shu Taira, Seiji Yano
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (5): 947–956.
https://doi.org/10.1158/1535-7163.MCT-18-0695
Published: 01 May 2019
View articletitled, Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Open the PDF for Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice in another window
Includes: Supplementary data
Journal Articles

Abstract B095: Antitumor activity of lenvatinib mesilate (LEN) via angiogenesis inhibition and tumor FGF signaling pathway in the human hepatocellular carcinoma models

Taisuke Hoshi, Masahiro Matsuki, Yuji Yamamoto, Yukinori Minoshima, Junji Matsui, Yasuhiro Funahashi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B095.
https://doi.org/10.1158/1535-7163.TARG-17-B095
Published: 01 January 2018
View articletitled, Abstract B095: Antitumor activity of lenvatinib mesilate (LEN) via angiogenesis inhibition and tumor FGF signaling pathway in the human hepatocellular carcinoma models
Journal Articles

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models

Saori Watanabe Miyano, Yuji Yamamoto, Kotaro Kodama, Yukiko Miyajima, Masaki Mikamoto, Takayuki Nakagawa, Hiroko Kuramochi, Setsuo Funasaka, Satoshi Nagao, Naoko Hata Sugi, Kiyoshi Okamoto, Yukinori Minoshima, Yusuke Nakatani, Yuki Karoji, Isao Ohashi, Yoshinobu Yamane, Toshimi Okada, Tomohiro Matsushima, Junji Matsui, Masao Iwata, Toshimitsu Uenaka, Akihiko Tsuruoka
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2630–2639.
https://doi.org/10.1158/1535-7163.MCT-16-0261
Published: 01 November 2016
View articletitled, E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Open the PDF for E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract A92: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors

Yu Kato, Kimiyo Tabata, Yusaku Hori, Sho Tachino, Kiyoshi Okamoto, Junji Matsui
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A92.
https://doi.org/10.1158/1535-7163.TARG-15-A92
Published: 01 December 2015
View articletitled, Abstract A92: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors
Journal Articles

Abstract A296: Eribulin mesylate suppresses experimental metastasis in the MX-1 human breast cancer model by reversing phenotypic states between epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET).

Taku Yoshida, Galina Kuznetsov, Takayuki KImura, Naoko H. Sugi, Hajime Shimizu, Yoichi Ozawa, Yoshiaki Sato, Taisuke Uehara, Hideki Watanabe, Kentaro Takahashi, Kentaro Matsuura, Mai Uesugi, Osamu Toyama, Mamoru Yanagimachi, Yasuhiro Funahashi, Junji Matsui
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A296.
https://doi.org/10.1158/1535-7163.TARG-13-A296
Published: 01 November 2013
View articletitled, Abstract A296: Eribulin mesylate suppresses experimental metastasis in the MX-1 human breast cancer model by reversing phenotypic states between epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET).